Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide

Ying S. Zou, Stephanie R. Fink, Kimberly J. Stockero, Sarah F. Paternoster, Stephanie A. Smoley, Han W. Tun, Craig B. Reeder, Ayalew Tefferi, Gordon W. Dewald

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

In clinical practice, whether FISH for EGR1 in interphase nuclei has similar efficacy to detect deletion 5q anomalies as conventional cytogenetic studies is unknown. We compared conventional cytogenetics and FISH for 145 patients with deletion 5q and detected this anomaly by both methods in 144. Nine patients with myelodysplasia were studied before and after treatment with Lenalidomide and results were concordant for 28 of 29 specimens. FISH did not detect anomalies other than deletion 5q in 31 patients. This study suggests FISH is useful to detect deletion 5q, but is not a substitute for conventional cytogenetics.

Original languageEnglish (US)
Pages (from-to)1185-1189
Number of pages5
JournalLeukemia Research
Volume31
Issue number9
DOIs
StatePublished - Sep 2007

Keywords

  • Acute leukemia
  • Deletion 5q
  • EGR1
  • Myelodysplasia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide'. Together they form a unique fingerprint.

  • Cite this